Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of zanzalintinib (XL092) alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony zaawansowany rak nerki z przerzutami
- •Wcześniejsze leczenie immunoterapią (przeciw PD-1), która nie zadziałała
- •Zdolność do samodzielnego funkcjonowania (ECOG 0-1)
- •Mierzalne ogniska nowotworu w badaniach obrazowych
- •Prawidłowe wyniki badań krwi i funkcji nerek
✗ Disqualifies
- •Poważne skutki uboczne z wcześniejszej immunoterapii (stopień 2 lub wyższy)
- •Inne leczenie systemowe po wcześniejszej immunoterapii
- •Niewystarczające wyniki badań laboratoryjnych (krew, nerki, wątroba)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
University of California San Diego
La Jolla, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, United States
Washington University School of Medicine
St Louis, United States
Columbia University Irving Medical Center
New York, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
Trial contact
Karie Runcie, MD
Allison Lipps
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.